98%
921
2 minutes
20
(Willd). R. Br. is a Chinese medicinal plant commonly used externally to treat inflammatory-related diseases such as arthritis, sores, and carbuncles. This study aimed to evaluate the anti-inflammatory activity of protopine total alkaloids (MPTAs) in (Willd.) R. Br. tests in rats with acute inflammation showed that MPTA (2.54 and 5.08 mg/kg) showed significant anti-inflammatory activity 6 h after carrageenan injection. Similarly, MPTA (3.67 and 7.33 mg/kg) showed significant anti-inflammatory activity in the mouse ear swelling test. In addition, the potential mechanisms of the anti-inflammatory effects of MPTA were explored based on network pharmacology and molecular docking. The two main active components of MPTA, protopine and allocryptopine, were identified, and the potential targets and signaling pathways of MPTA's anti-inflammatory effects were initially revealed using tools and databases (such as SwissTargetPrediction, GeneCards, and STRING) combined with molecular docking results. This study provides the basis for the application of MPTA as an anti-inflammatory agent.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9294607 | PMC |
http://dx.doi.org/10.3389/fvets.2022.935201 | DOI Listing |
Adv Emerg Nurs J
September 2025
Author Affiliations: Department of Clinical Pharmacy and Outcomes Sciences, College of Pharmacy, University of South Carolina (Dr Weant); and Department of Pharmacy, University of North Carolina Health, Chapel Hill, North Carolina (Dr Gregory).
Migraine is an often-disabling condition and a common presentation to the Emergency Department (ED). Rapid and effective treatment are essential to reduce symptom burden, prevent recurrence, and improve patient outcomes. This review provides a comprehensive, evidence-based overview of the pharmacologic management of acute migraine in the ED, including first-line therapies, rescue medications, adjunctive care strategies, and considerations for special populations.
View Article and Find Full Text PDFEpidemiol Serv Saude
September 2025
Universidade Federal de Minas Gerais, Departamento de Farmácia Social, Belo Horizonte, MG, Brazil.
Objectives: To assess the persistence and time until discontinuation of biological drugs used by people with ankylosing spondylitis treated in the Brazilian Unified Health System and to investigate the factors associated with them.
Methods: Data were collected from an open historical cohort between 2018 and 2023 on the administrative processes required for requesting medicines from the specialized component of pharmaceutical assistance in Minas Gerais, Brazil. Sociodemographic and clinical data and treatment history were collected.
J Infect Dis
September 2025
University of Veterinary Medicine Vienna, Infectiology, Vienna, Austria.
Frequent emergence of respiratory viruses with pandemic potential, like SARS-CoV-2 or influenza, underscores the need for broad-spectrum prophylaxis. Existing vaccines show reduced efficacy against newly emerged variants, and the ongoing risk of new outbreaks highlights the importance of alternative strategies to prevent infection and viral transmission. As respiratory viruses primarily enter through the nose, formulations targeting the nasal epithelium are attractive candidates to neutralize pathogens and thus prevent or minimize infection.
View Article and Find Full Text PDFJ Crohns Colitis
September 2025
Department of Gastroenterology, University Hospital of Marseille Nord, Assistance Publique-Hôpitaux de Marseille (AP-HM), Aix-Marseille University, Marseille, France.
Background And Aims: While this strategy is frequently used for other biologics, real-world evidence on subcutaneous (SC) vedolizumab (VDZ) dose intensification in inflammatory bowel disease (IBD) is lacking. This study aimed to assess the effectiveness and safety of SC VDZ intensification.
Methods: We conducted a retrospective study in 25 centers including all patients with active ulcerative colitis (UC) or Crohn's disease (CD) (defined by PRO2), and incomplete or loss of response to SC VDZ 108mg EOW when the drug was intensified.
JAMA Netw Open
September 2025
Division of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla.
Importance: Janus kinase (JAK) inhibitors are highly effective medications for several immune-mediated inflammatory diseases (IMIDs). However, safety concerns have led to regulatory restrictions.
Objective: To compare the risk of adverse events with JAK inhibitors vs tumor necrosis factor (TNF) antagonists in patients with IMIDs in head-to-head comparative effectiveness studies.